首页> 外文期刊>Biotechnology Progress >Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model
【24h】

Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model

机译:抗上皮细胞粘附分子RNA适体 - 缀合的脂质体多柔比蛋白作为患有结肠癌肿瘤模型的小鼠有效的靶向治疗

获取原文
获取原文并翻译 | 示例
       

摘要

To overcome the lack of selectivity and nonspecific biodistribution of drugs in the body, targeted delivery of chemotherapeutic agents with aptamers is a very effective method. In this strategy, aptamers could be specifically identified and attach to targeted molecules on the cancerous cells and deliver the chemotherapeutic agents to desired tissue with minimal or no damage to the normal cells. In this study, we designed anti-epithelial cell adhesion molecule (EpCAM) RNA aptamer conjugated PEGylated liposomal doxorubicin (ER-lip) to investigate its in vitro and in vivo anticancer abilities. Data showed that EpCAM aptamer was able to enhance cell uptake and cytotoxic effects of Dox in C26 cell line. The biodistribution study indicated that ER-lip enhanced the tumor accumulation of Dox compared to Caelyx. Also, double staining of isolated tumor cells with anti-CD44-PE-cy5 and anti-EpCAM Cy-7 antibodies indicated that tumor cells expressed a high level of EpCAM(+) CD44(+) cells (p <= .001) compared to cultured C26 cell line. in vivo results showed that ER-lip promoted survival and reduced tumor growth rate in animal model compared to Caelyx. In conclusion, these results suggested that the ER-lip could be served as promising formulation for the treatment of cancers with the high expression of EpCAM.
机译:为了克服身体中药物的缺乏选择性和非特异性生物分布,有针对性的递送具有适体的化学治疗剂是一种非常有效的方法。在该策略中,可以具体鉴定适体和附着于癌细胞上的靶分子,并将化学治疗剂递送至所需的组织,以最小或对正常细胞造成损伤。在该研究中,我们设计了抗上皮细胞粘附分子(EPCAM)RNA适体缀合的聚乙二醇化脂质体DOXORUBININ(ER-LIP),以研究其体外和体内抗癌能力。数据显示,EPCAM适体能够在C26细胞系中增强DOX的细胞吸收和细胞毒性作用。生物分布研究表明,与Caelyx相比,ER-LIP增强了DOX的肿瘤积累。此外,用抗CD44-PE-CY5和抗EPCAM CY-7抗体的分离肿瘤细胞的双染色表明肿瘤细胞表达了高水平的EPCAM(+)CD44(+)细胞(P <= .001)培养C26细胞系。在体内结果表明,与Caelyx相比,ER-LIP促进了动物模型中的存活率和降低的肿瘤生长速率。总之,这些结果表明,ER-唇可以作为对癌症的高表达治疗癌症的有希望的制剂。

著录项

  • 来源
    《Biotechnology Progress》 |2021年第3期|共12页
  • 作者单位

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Fac Med Dept Med Biotechnol Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

    Mashhad Univ Med Sci Pharmaceut Technol Inst Nanotechnol Res Ctr Mashhad Razavi Khorasan Iran;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 生物科学;
  • 关键词

    EpCAM; liposomal doxorubicin; active targeting; RNA aptamer;

    机译:EPCAM;脂质体DOXORUBICIN;活性靶向;RNA适体;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号